Merck KGaA
https://www.merckgroup.com/en
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Merck KGaA
Twitchy Times At GSK As Activist Investor Takes Big Stake
GlaxoSmithKline's market value has slipped in the past three years and the number of failures in the clinic have grown. The major's leadership will be casting nervous glances towards a major shareholder that has a reputation for aggressive restructuring calls.
GSK's ICOS Agonist Disappointment Another Setback For Anticancer Ambitions
GlaxoSmithKline has discontinued treatment with its ICOS agonist feladilimab in the Phase II INDUCE-3 trial upon the recommendation of the study’s data monitoring committee, another setback for the big pharma’s plans to become a major force in the cancer therapy area.
Artios On How To Strike A Deal With Big Pharma
With the number of deals being inked in biopharma continuing apace, the UK firm spoke to Scrip about how to negotiate the line between what big pharma wants and what a biotech is likely to get.
Reimbursement Dispute Between Novitas And iRhythm Hits An Impasse
Local Medicare carrier Novitas raised its reimbursement rates for continuous cardiac monitoring, but iRhythm has concluded the rates are still too low and is preparing to discontinue serving this Medicare segment.
Company Information
- Industry
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Pharmaceuticals
- Drug Delivery
- Nutraceuticals
-
Biotechnology
- Synthesis Technologies, Production Processes
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
- Other Names / Subsidiaries
-
- Acadiana Ventures Inc.
- Allergopharma Joachim Ganzer KG
- AmpTec GmbH
- Asceneuron
- EMD Pharmaceuticals
- Grzybowski Scientific Inventions (GSI)
- Intermolecular Inc
- JRH Biosciences
- Merck Hoei Ltd.
- Millipore
- MilliporeSigma
- Ormet Circuts Inc.
- Serono
- EMD Serono, Inc.
- Sigma-Aldrich
- Versum Materials, Inc.